Anticoagulant effects of Idraparinux after termination of therapy for prevention of recurrent venous thromboembolism: Observations from the van Gogh trials

European Journal of Clinical Pharmacology

Volumn 64, Issue 6, 2008, Pages 555-563

  Harenberg, Job ^a   Jörg, Ingrid ^a   Vukojevic, Yvonne ^a   Mikus, Gerd ^b   Weiss, Christel ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

Anticoagulants; Anticoagulation; Idraparinux; Pharmacodynamics; Thrombosis; Venous thromboembolism

Indexed keywords

ANTITHROMBIN; ANTIVITAMIN K; CHROMOGENIC SUBSTRATE; ENOXAPARIN; IDRAPARINUX; LOW MOLECULAR WEIGHT HEPARIN; PENTASACCHARIDE; PROTHROMBIN; WARFARIN;

ADULT; AGED; ANTICOAGULATION; AREA UNDER THE CURVE; ARTICLE; BLEEDING; BLOOD CLOTTING TIME; BLOOD SAMPLING; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATININE CLEARANCE; DISTRIBUTION VOLUME; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG EFFECT; DRUG HALF LIFE; DRUG PROTEIN BINDING; DRUG WITHDRAWAL; FEMALE; HUMAN; LONG TERM CARE; MALE; MULTICENTER STUDY; PARTIAL THROMBOPLASTIN TIME; PLASMA CLEARANCE; PRIORITY JOURNAL; PROTHROMBIN TIME; RANDOMIZED CONTROLLED TRIAL; TREATMENT WITHDRAWAL; VENOUS THROMBOEMBOLISM;

ANTICOAGULANTS; HALF-LIFE; HUMANS; OLIGOSACCHARIDES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RECURRENCE; VENOUS THROMBOEMBOLISM;

EID: 42549097091     PISSN: 00316970     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00228-008-0463-0     Document Type: Article

References (29)

1. Hirsh J, Raschke R (2004) Heparin and low-molecular-weight heparin: the seventh ACCP conference on antithrombotic and thrombolytic therapy. Chest 126:188S-203S
2. Büller HR, Agnelli G, Hull RD, Hyers TM, Prins MH, Raskob GE (2004) Antithrombotic therapy for venous thromboembolic disease: the seventh ACCP conference on antithrombotic and thrombolytic therapy. Chest 126:401S-428S
3. Warkentin TE, Greinacher A (2004) Heparin-induced thrombocytopenia: recognition, treatment, and prevention: the seventh ACCP conference on antithrombotic and thrombolytic therapy. Chest 126:311S-337S
4. Kearon C, Gent M, Hirsh J, Weitz J, Kovacs MJ, Anderson DR, Turpie AG, Green D, Ginsberg JS, Wells P, MacKinnon B, Julian JA (1999) A comparison of three months of anticoagulation with extended anticoagulation for a first episode of idiopathic venous thromboembolism. N Engl J Med 340:901-907
5. Ansel Jl, Hirsh J, Poller L, Bussey H, Jacobson A, Hylek E (2004) The pharmacology and management of the vitamin K antagonists: the seventh ACCP conference on antithrombotic and thrombolytic therapy. Chest 126:204S-233S
6. Kearon C, Ginsberg JS, Kovacs MJ, Anderson DR, Wells P, Julian JA, MacKinsson B, Weitz JI, Crowther MA, Dolan S, Turpie AG, Geerts W, Solymoss S, van Nguyen P, Demers C, Kahn SR, Kassis J, Rodger M, Hambleton J, Gent M (2003) Extended low-intensity anticoagulation for thrombo-embolism investigators. Comparison of low-intensity warfarin therapy with conventional-intensity warfarin therapy for long-term prevention of recurrent venous thromboembolism. N Engl J Med 349:631-639
7. Ridker PM, Goldhaber SZ, Danielson E, Rosenberg Y, Eby CS, Deitcher SR, Cushman M, Moll S, Kessler CM, Elliott CG, Paulson R, Wong T, Bauer KA, Schwartz BA, Miletich JP, Bounameaux H, Glynn RJ (2003) PREVENT Investigators. Long-term, long-intensity warfarin therapy for the prevention of recurrent venous thromboembolism. N Engl J Med 348:1425-1434
8. Schulman S, Wahlander K, Lundstrom T, Clason SB, Eriksson H, THRIVE III Investigators (2003) Secondary prevention of venous thromboembolism with the oral direct thrombin inhibitor ximelagatran. N Engl J Med 349:1713-1721
9. Weitz JI, Bates SM (2005) New anticoagulants. J Thromb Haemost 3:1843-1853
10. Herbert JM, Herault JP, Bernat A et al (1988) Biochemical and pharmacological properties of SANORG 34006, a potent and long-acting synthetic pentasaccharide. Blood 91:4197-4205
11. de Kort M, Buijsman RC, van Boeckel CA (2005) Synthetic heparin derivatives as new anticoagulant drugs. Drug Discov Today 10:769-779
12. Ma Q, Fareed J (2004) Idraparinux sodium. Sanofi-Aventis. IDrugs 7:1028-1034
13. Persist Investigators (2004) A novel long-acting synthetic factor Xa inhibitor (SanOrg340006) to replace warfarin for secondary prevention in deep vein thrombosis: a Phase II evaluation. J Thromb Haemost 2:47-53
14. The van Gogh Investigators (2007) Idraparinux versus standard therapy for venous thromboembolic disease. N Engl J Med 357:1094-1104
15. The van Gogh Investigators (2007) Extended prophylaxis of venous thromboembolism with idraparinux. N Engl J Med 357:1105-1112
16. Harenberg J, Giese C, Dempfle CE, Stehle G, Heene DL (1988) Monitoring of heparin and low molecular weight heparin with capillary and venous whole blood. Thromb Haemost 60:377-381
17. Harenberg J, Giese C, Hagedorn A, Traeger I, Fenyvesi T (2007) Determination of antithrombin-dependent factor Xa inhibitors by prothrombin-induced clotting time. Semin Thromb Hemost 33:503-507
18. Oberwittler H, Hirschfeld-Warneken A, Wesch R, Willerich H, Teichert L, Lehr KH, Ding R, Haefeli WE, Mikus G (2007) Significant pharmacokinetic and pharmacodynamic interaction of warfarin with the NO-independent sGC activator HMR1766. J Clin Pharmacol 47:70-77
19. Van Amsterdam RGM, Burggraaf J, Borm GF, Schoemaker HC, de Greef HJMM, Faaij RA, Nelissen JMDT (2004) A phase I multiple dose study to investigate the safety, tolerance and pharmacokinetics of 10 mg SC SanOrg34006 in male and female volunteers with a history of VTE, recently discharged from oral anticoagulant treatment. Clinical Trial Report on Protocol 64703. R&DRR NL0028967. Organon, Oss
20. Fairclough A (2002) The in vitro binding of [35-S]-SanOrg3400S (SR34006A) in rat, monkey and human (normal and AT III depleted) plasma. Research report 767.5.017. Sanofi-Synthelabo, France
21. Hjelm R, Schedin-Weiss S (2007) High affinity interaction between a synthetic, highly negatively charged pentasaccharide and R- or â-antithrombin is predominantly due to nonionic interactions. Biochemistry 46:3378-3384
22. van Boeckel CAA, Petitou M (1993) The unique antithrombin III binding domain of heparin: a lead to newsynthetic antithrombotics. Angew Chem Int Ed Engl 32:1671-1818
23. Jeske W, Fareed J (1999) In vitro studies on the biochemistry and pharmacology of low molecular weight heparins. Semin Thromb Hemost 25 [Suppl 3]:27-33
24. Fenyvesi T, Jörg I, Harenberg J (2002) Effect of phenprocoumon on monitoring of lepirudin, argatroban, melagatran and unfractionated heparin with the PiCT method. Pathophysiol Haemost Thromb 32:174-179
25. Thomas DP, Merton RE, Lewis WE, Barrowcliffe TW (1981) Studies in man and experimental animals of a low molecular weight heparin fraction. Thromb Haemost 45:214-218
26. Harenberg J, Gnasso A, de Vries JX, Zimmermann R, Augustin J (1985) Anticoagulant and lipolytic effects of a low molecular weight heparin fraction. Thromb Res 39:683-692
27. Ma Q, Tobu M, Schultz C, Jeske W, Hoppensteadt D, Walenga J, Cornelli U, Lee J, Linhardt R, Hanin I, Fareed J (2007) Molecular weight dependent tissue factor pathway inhibitor release by heparin and heparin oligosaccharides. Thromb Res 119:653-661
28. Walenga JM, Jeske WP, Samama MM, Frapaise FX, Bick RL, Fareed J (2002) Fondaparinux: a synthetic heparin pentasaccharide as a new antithrombotic agent. Expert Opin Investig Drugs 11:397-407
29. Savi P, Herault JP, Duchaussoy P, Millet L, Petitou M, Schaeffer P, Bono F, Herbert JM (2007) Reversible biotinylated oligosaccharides, a new approch for a better management of the anticoagulant therapy (abstract). J Thromb Haemost [Suppl] P-W-645